Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic reorganization to prioritize its portfolio of late-stage pipeline ...

As part of this portfolio reorganization, NTLA is planning to prioritize the development of its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...

Intellia Therapeutics: Gene-Editing to Treat Cancer and Genetic Diseases Another leader in gene editing is Intellia Therapeutics Inc. (NASDAQ: NTLA), which focuses on treating genetic diseases ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...

Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...